The Novo Nordisk Foundation, the philanthropic arm of the Danish pharmaceutical giant, announced Dec. 18 that it has committed $260 million toward the development and improvement of respiratory virus vaccines.
Read the full post on Becker's Hospital Review - Healthcare News
